Instrument Inactif

Communiqués A1M Pharma AB Nasdaq Stockholm

Actions

Cours en clôture Nasdaq Stockholm Autres places de cotation
- ^SEK	-

27/05	Guard Therapeutics annonce que la revue scientifique American Journal of Physiology ? Renal Physiology publie un article résumant les résultats précliniques importants de son médicament clinique candidat RMC-035.	CI
08/05	Guard Therapeutics International AB (publ) annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Guard Therapeutics carries out a directed share issue of approximately SEK 60 million and intends to carry out a repair issue	17/06	AQ
Guard Therapeutics research published in American Journal of Physiology – Renal Physiology	27/05	AQ
Guard Therapeutics receives its first regulatory approval for the phase 2b study POINTER	15/04	AQ
Guard Therapeutics presented development strategy and new preclinical results at R&D Update	31/01	AQ
Invitation to Guard Therapeutics’ R&D Update on January 30	18/01	AQ
FDA provides positive feedback to Guard Therapeutics regarding the continued development plan for RMC-035	15/01	AQ
Guard Therapeutics presents the Nomination Committee for 2024	07/12	AQ
Guard Therapeutics presents late breaking clinical trial abstract at ASN Kidney Week 2023	23/10/23	AQ
Guard Therapeutics provides more information on the development strategy for RMC-035	28/09/23	AQ
Guard Therapeutics reports robust efficacy of RMC-035 in Phase 2 (AKITA) and advances clinical development program	19/09/23	AQ
Last patient visit completed in Guard Therapeutics' clinical Phase 2 study AKITA	14/07/23	AQ
Study results with Guard Therapeutics’ RMC-035 in kidney transplantation confirm previously positive data analysis	14/06/23	AQ
Guard Therapeutics provides updated information on the phase 2 study AKITA	02/05/23	AQ
Guard Therapeutics closes its phase 2 clinical trial AKITA following DMC recommendation	14/04/23	AQ
Guard Therapeutics presents positive clinical data with RMC-035 in patients undergoing kidney transplantation	16/03/23	AQ
Results from Guard Therapeutics' Phase 1b study in cardiac surgery published in Kidney International Reports	20/02/23	AQ
First US patient dosed in Guard Therapeutic’s Phase 2 AKITA study	16/02/23	AQ
Half of the patients dosed in the Phase 2 AKITA study	10/02/23	AQ
Guard Therapeutics receives patent approval for RMC-035 in China	09/01/23	AQ
Guard Therapeutics presents the Nomination Committee for 2023	20/12/22	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués A1M Pharma AB Nasdaq Stockholm

Actions

Communiqués

Filtres